Ambeed.cn

首页 / / / / Cladribine

克拉利宾 /Cladribine {[allProObj[0].p_purity_real_show]}

货号:A410468 同义名: 克拉屈滨 / 2-Chloro-2′-deoxyadenosine;CldAdo

Cladribine is an adenosine deaminase inhibitor used to treat hairy cell leukemia and multiple sclerosis. For U266, RPMI8226, and MM1.S cells, its IC50 are approximately 2.43 μM, 0.75 μM, and 0.18 μM, respectively.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Cladribine 化学结构 CAS号:4291-63-8
Cladribine 化学结构
CAS号:4291-63-8
Cladribine 3D分子结构
CAS号:4291-63-8
Cladribine 化学结构 CAS号:4291-63-8
Cladribine 3D分子结构 CAS号:4291-63-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Cladribine 纯度/质量文件 产品仅供科研

货号:A410468 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell Host Microbe, 2024. Ambeed. [ A163338 ]
Cancer Res., 2024. Ambeed. [ A295334 ]
J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >
产品名称 DNA synthesis helicase RdRp ribonucleotide reductase tRNA synthetase YB-1 其他靶点 纯度
Fexinidazole 98%
Daptomycin 98%
Blasticidin S·HCl 98%
Metronidazole 98%
Daunorubicin HCl +++

DNA synthesis, Ki: 20 nM

98%
Triglycidyl isocyanurate p53 98+%
Nedaplatin 99%+
Bendamustine 98+%
Trifluridine 98%
Robinetin 99%+
Carboplatin 99%
Cidofovir 99%
Cisplatin 99%
Cytarabine ++++

DNA synthesis, IC50: 16 nM

98%
Acelarin ++++

DNA synthesis, EC50: 0.2 nM

99%+
Oxaliplatin 98%
YK-4-279 99%+
ML216 +

BLMfull-length, IC50: 2.98 μM

BLM636-1298, IC50: 0.97 μM

99%+
RK-33 98%
Brr2-IN-3 99%+
Phen-DC3 Trifluoromethanesulfonate 98%
Favipiravir 97%
Suramin sodium salt ++

RdRp, IC50: 0.26 μM

99%+
Clofarabine ++

Ribonucleotide reductase, IC50: 65 nM

97%
Didox 98%
(E)-3-AP 97%
Halofuginone +++

prolyl-tRNA synthetase, Ki: 18.3nM

99%+
BC-LI-0186 +++

Leucyl-tRNA synthetase, Kd: 42.1 nM

Leucyl-tRNA synthetase, IC50: 46.11 nM

98%
SU056 +

YB-1, IC50: 1.73 μM

98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

Cladribine 生物活性

描述 Adenosine Deaminase (ADA) is a housekeeping enzyme in purine metabolism that is unique and essential in the differentiation and maturation of the immune system and thus can be the cause of human severe combined immune deficiency. Cladribine is a well-known ADA inhibitor against lymphoproliferative disorders with IC50 for U266, RPMI8226, or MM1.S cells approximately 2.43, 0.75, or 0.18 μM respectively. In U266 cells, cladribine treatment gradually increased the percentage of cells in the G1 phase from 42% to 45%, 62%, 66% at 24, 48, 72 hrs, respectively. And the percentage of cells in S phase reduced from 50% to 36%, 26%, 23% at 24, 48, 72 hrs, respectively. The percentage of cells in G2/M phase increased from 8% to 19% at 24 hrs and then decreased to 11% at 72 hrs. Cladribine also induced the cells’ apoptosis with percentages of 5%, 15%, 21% and 33% when U266 cells were untreated or treated with 2, 5, 10 μM of cladribine, respectively. In RPMI8226 cells, 2μM cladribine treatment led to 14% increasing of cells in G1 phase and 18% decreasing in S phase at 24 hrs. And the percentages of apoptosis cells were improved in a dose-dependent manner when treated with 0.5, 1, 2 μM of cladribine, respectively. Similar cell cycle induction results with treatment of 0.5μM cladribine and apoptosis induction results with treatment of 0.1, 0.2, 0.5μM cladribine were observed in MM1.S cells. Furthermore, treatment of 0.2μM cladribine could be effective in reducing P-STAT3 in MM1.S cells while the concentrations were 1 μM in RPMI8226 and 2 μM in U266 cells[1]. When applied the cladribine in four patients with systemic mastocytosis (SM), the IC50 for HMC-1.1 and HMC-1.2 cells were 300 nM and 10 nM respectively, suggesting that the codon 816 mutant may improve the responses to this drug. Cell apoptosis were also induced when treated with 0.5 and 1 μM of cladribine, the survival of HMC-1.2 cells was much stronger. The expression of apoptosis related CD95 in HMC-1.2 cells were also substantially promoted by 0.5 μM cladribine with stimulation index (SI) raised from 1 to 3 and with that of CD164 raised from 1 to 2. The expression SI of CD87 only in HMC-1.1 cells were raised from 1 to 5, while no effect on CD87 was observed in HMC-1.2 cells[6].

Cladribine 细胞研究

细胞系 浓度 检测类型 检测时间 活动说明 数据源
BT549 cells Cytotoxicity assay 3 days Cytotoxicity against human BT549 cells after 3 days by MTT assay, IC50=0.123 μM 21711054
CCRF-CEM cell lines Cytotoxicity assay Compound was tested for cytotoxicity against CCRF-CEM cell lines, IC50=0.003 μM 1732556
CCRF-CEM cells Cytotoxicity assay 72 h Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay, IC50=0.0005 μM 21840722
CEM-DNR-bulk cells Cytotoxicity assay 3 days Cytotoxicity against human CEM-DNR-bulk cells after 3 days by MTT assay, IC50=0.352 μM 21711054

Cladribine 动物研究

Dose Mice: 60 mg/kg[3] (s.c.); 20 mg/kg[3] (p.o.); 0.5 mg/kg[4] (i.p.)
Administration s.c., p.o., i.p.
Pharmacokinetics
Animal Mice[5]
Dose 30 mg/kg (male)
Administration p.o.
AUC24h 4108 h·ng/ml
Cz 52.7 ng/ml
Tmax 1 h
Cmax 4580 ng/ml

Cladribine 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02096055 Leukemia Phase 2 Active, not recruiting April 2026 United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT00691652 Lymphoma Phase 1 Phase 2 Terminated - United States, Oregon ... 展开 >> Knight Cancer Institute at Oregon Health and Science University Portland, Oregon, United States, 97239-3098 收起 <<
NCT00117598 Lymphoma Phase 3 Completed - -

Cladribine 参考文献

[1]Ma J. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer. 2011 Jun 16;11:255. doi: 10.1186/1471-2407-11-255.

[2]Guchelaar HJ, Vermes I, et al. Apoptosis-and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model. Cancer Chemother Pharmacol. 1998;42(1):77-83.

[3]Scheible H, Laisney M, et al. Comparison of the in vitro and in vivo metabolism of Cladribine (Leustatin, Movectro) in animals and human. Xenobiotica. 2013 Dec;43(12):1084-94.

[4]Hayes CD, Dey D, et al. Chronic cladribine administration increases amyloid beta peptide generation and plaque burden in mice. PLoS One. 2012;7(10):e45841.

[5]Cladribine

[6]Böhm A. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol. 2010 Sep;38(9):744-55. doi: 10.1016/j.exphem.2010.05.006. Epub 2010 May 27.

Cladribine 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.50mL

0.70mL

0.35mL

17.50mL

3.50mL

1.75mL

35.00mL

7.00mL

3.50mL

Cladribine 技术信息

CAS号4291-63-8
分子式C10H12ClN5O3
分子量 285.687
别名 克拉屈滨 ;2-Chloro-2′-deoxyadenosine;CldAdo;* 2chlorodeoxyadenosine.;2CdA. Code name: RWJ26251. Chemical structure names: * 2chloro2deoxyadenosine;Leustatine. Abbreviations: 2CDA;Cladribina. US brand name: Leustatin. Foreign brand names: Leustat;NSC 105014;Jk 6251;​2-Chlorodeoxyadenosine;RWJ 26251;2CdA
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,2-8°C

溶解度

DMSO: 30 mg/mL(105.01 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 10 mg/mL(35 mM),配合低频超声助溶

动物实验配方

5% DMSO+30% PEG 300+1% Tween 80+water 10 mg/mL

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。